FBRX news

Latest 2 stories · newest Jul 9, 2026

FBRX

Forte Biosciences' FB102 achieves statistically significant results in phase 1b vitiligo trial

Forte Biosciences announced positive results from a double-blind placebo-controlled study where FB102 improved vitiligo severity by 29.6% through week 24. Continued post-treatment efficacy and safety support the drug's therapeutic potential.

Other Jul 9, 2026 sentiment +0.80 SEC filing ↗

FBRX

Forte Biosciences amends 2021 equity incentive plan effective April 28, 2026.

Forte Biosciences adopted an amended and restated 2021 equity incentive plan to provide equity awards to employees, directors, and consultants. The plan update may impact future compensation structures and shareholder dilution for the bioscience company.

Other Jun 2, 2026 sentiment 0.00 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same FBRX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/FBRX/newsSTART FREE